Biotron Limited (BIT) - Financial and Strategic SWOT Analysis Review
Reference Code: GDPH18325FSA Publication Date: OCT 2012
Level 2, 66 Hunter Street Phone +61 2 93003344 Revenue 0.45 (million AUD)
Sydney, NSW Fax +61 2 92216333 Net Profit -2.38 (million AUD)
2000 Website www.biotron.com.au Employees 4
BIT [Australian Stock Pharmaceuticals &
Australia Exchange Industry
Exchange (Sydney)] Healthcare
Company Overview
Biotron Limited (Biotron) is a biotechnology company. The company undertakes the development and commercialization of novel
therapeutics and diagnostics that address a range of significant health issues. Its intermediate and applied technologies and
research and development programs are used in treatment of hepatitis C virus (HCV), human immunodeficiency virus (HIV),
Dengue virus and Influenza virus. Its offers a wide portfolio of clinical and preclinical antiviral programs that include drugs
targeting viral proteins, namely, p7, Vpu, and M protein. The company's flagship product, BIT225 is under development stage and
has completed Phase 2a clinical trial in HCV.
Key Executives SWOT Analysis
Name Title Biotron Limited, SWOT Analysis
Michelle Miller, Ph.D. Chief Executive Officer Strengths Weaknesses
Bruce Hundertmark Director
Robust Research and Dependence on Government
Denis Wade Director Development Platform Grants
Susan Pond Director
Robust Patent Portfolio History of Losses
Rob Thomas Director
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData Opportunities Threats
Share Data Agreements and Collaborations Technological Obsolescence
Biotron Limited
Focus on Major Therapeutic Uncertainties in R&D
Share Price (AUD) as on 18-Oct- 0.13 Areas
2012
EPS (AUD) -0.01
Source: Annual Report, Company Website, Primary and Secondary Research,
Market Cap (million AUD) 29 GlobalData
Enterprise Value (million AUD) 21
Shares Outstanding (million) 228
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Biotron Limited (BIT) - Financial and Strategic SWOT Analysis Reference Code: GDPH18325FSA
Review
Source : www.globalcompanyintelligence.com Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 3
List of Figures ................................................................................................................................................................................. 3
Section 1 - About the Company.......................................................................................................................................................... 4
Biotron Limited - Key Facts ................................................................................................................................................................ 4
Biotron Limited - Key Employees ....................................................................................................................................................... 5
Biotron Limited - Key Employee Biographies ..................................................................................................................................... 6
Biotron Limited - Major Products and Services................................................................................................................................... 7
Biotron Limited - Pharmaceutical Pipeline Products Data .................................................................................................................. 8
Biotron Limited, Pipeline Products by Therapy Area ....................................................................................................................... 8
Biotron Limited, Pipeline Products by Development Phase ............................................................................................................ 9
Biotron Limited - History ................................................................................................................................................................... 11
Biotron Limited - Company Statement .............................................................................................................................................. 13
Biotron Limited - Locations And Subsidiaries ................................................................................................................................... 15
Head Office ................................................................................................................................................................................... 15
Other Locations & Subsidiaries ..................................................................................................................................................... 15
Section 2 – Company Analysis ......................................................................................................................................................... 16
Biotron Limited - Business Description ............................................................................................................................................. 16
Biotron Limited - Corporate Strategy ................................................................................................................................................ 17
Biotron Limited - SWOT Analysis ..................................................................................................................................................... 18
SWOT Analysis - Overview........................................................................................................................................................... 18
Biotron Limited - Strengths ........................................................................................................................................................... 18
Strength - Robust Research and Development Platform........................................................................................................... 18
Strength - Robust Patent Portfolio............................................................................................................................................. 18
Strength - Improved Liquidity Position ....................................................................................................................................... 18
Biotron Limited - Weaknesses ...................................................................................................................................................... 18
Weakness - Dependence on Government Grants ..................................................................................................................... 18
Weakness - History of Losses ....